RxDoctor Payments DataLook up a doctor →

Aristotel Pena-Miches, MD

Neurology with Special Qualifications in Child Neurology · Monroe, LANPI 1326175829

Payments from drug & device makers

$207,113in general payments, 2019–2025

Across 581 payments — averaging $356.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biogen$196K
  • UCB, Inc.$3K
  • Catalyst Pharmaceuticals, Inc.$1K
  • Jazz Pharmaceuticals Inc.$1K
  • Livanova USA, Inc.$969
  • Eisai Inc.$782
  • plus $3K from 26 others

What the payments were for

  • Consulting fees$12,6186%
  • Speaking & faculty fees$151,98573%
  • Travel & lodging$33,21316%
  • Food & beverage$8,9804%
  • Education$3180%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$207,113 in reported general payments places this provider in the 90th percentile of 30 neurology with special qualifications in child neurology providers in Louisiana.

See all neurology with special qualifications in child neurology providers in Louisiana

Medicare billing

Part B allowed, 2024
$3,100
Medicare patients
17
Services billed
28

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FycompaPerampanel81$122,937
EpidiolexCannabidiol (Cbd)13$117,935
BriviactBrivaracetam40$67,104
AptiomEslicarbazepine Acetate11$17,182
NayzilamMidazolam11$6,749
Oxcarbazepine61$6,145
Divalproex Sodium65$4,107
Lacosamide51$3,728
Levetiracetam77$1,505
Carbamazepine ErCarbamazepine14$1,215
Divalproex Sodium ErDivalproex Sodium32$664
Risperidone50$499
LevocarnitineLevocarnitine (With Sugar)16$374
Zolpidem Tartrate70$303
Thioridazine Hcl13$239

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Eisai Inc.Fycompa$782$122,93781 claims
UCB, Inc.Briviact, Nayzilam$3,463$73,85351 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 30 neurology with special qualifications in child neurology providers in Louisiana.

Other neurology with special qualifications in child neurology in Monroe

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →